6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphtyl-1'(S))ethyl]-4(R)-(dimethyltertbutylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphtyl-1'(S))ethyl]-4(R)-(dimethyltertbutylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one
• 英文别名: (4R,6R)-4-[tert-butyl(dimethyl)silyl]oxy-6-[2-[(1S,2S,6R,8S)-8-hydroxy-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl]oxan-2-one
• 化学式: C₂₅H₄₂O₄Si
• 分子量: 434.692
• InChiKey: MJLUKJALEPACMG-UCQOJCJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.63
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphtyl-1'(S))ethyl]-4(R)-(dimethyltertbutylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one 生成 (4R,6R)-4-[tert-butyl(dimethyl)silyl]oxy-6-[2-[(1S,2S,6S,8S)-8-hydroxy-2,6-dimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]ethyl]oxan-2-one
  参考文献：
  名称：

  SCHUDA, ANN D.;VERHOEVEN, THOMAS R.;SHINKAI, ICHIRO

  摘要：

  DOI：
• 作为产物：
  描述：

  洛伐他汀 在 咪唑 、 水 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 45.0h， 生成 6(R)-[2-(8'(S)-hydroxy-2'(S),6'(R)-dimethyl-1',2',6',7',8',8a'(R)-hexahydronaphtyl-1'(S))ethyl]-4(R)-(dimethyltertbutylsilyloxy)-3,4,5,6-tetrahydro-2H-pyran-2-one
  参考文献：
  名称：

  HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND

  摘要：

  本发明描述了式(I)的化合物，其羟基酸形式，所述羟基酸的药学上可接受的盐，以及所述化合物及其羟基酸形式的药学上可接受的前药和溶剂化物，特别是所述化合物、其羟基酸形式、盐等用于预防：神经退行性疾病、认知障碍、与不良氧化相关的疾病、年龄相关的病理过程和早衰、心血管疾病，如动脉粥样硬化、心房颤动、血脂异常、高胆固醇血症、高脂血症和高甘油三酯血症、炎症或炎症过程，或癫痫、癫痫发作和惊厥。

  公开号：

  US20130197073A1

文献信息

• [EN] IMPROVED PROCESS FOR PRODUCING SIMVASTATIN<br/>[FR] PROCEDE AMELIORE DE PRODUCTION DE SIMVASTATINE
  申请人：JUBILANT ORGANOSYS LTD

  公开号：WO2005077928A1

  公开（公告）日：2005-08-25

  Disclosed herein is an industrially feasible process for producing HMG-CoA reductase inhibitor, simvastatin, via an improved acylation process using lovastatin ammonium salt as a starting material. The process comprising treating lovastatin ammonium salt with a base to obtain the compound of formula [III], lactonizing the compound of the formula [III] to obtain compound of formula [IV], selectively protecting the hydroxyl group of the compound of formula [IV] to obtain compound of formula [V], acylating the compound of formula [V] with dimethylbutyrylchloride using potassium halide in presence of a solvent to obtain compound of formula [VI], deprotecting compound of formula [VI] followed by hydrolysis to obtain simvastatin ammonium salt of formula [VII] which is lactonized to obtain simvastatin.

  本文披露了一种工业上可行的过程，通过改进的酰化过程利用洛伐他汀铵盐作为起始物质生产HMG-CoA还原酶抑制剂辛伐他汀。该过程包括将洛伐他汀铵盐与碱处理以获得式[III]的化合物，使式[III]的化合物内酯化以获得式[IV]的化合物，选择性保护式[IV]的羟基以获得式[V]的化合物，使用溶剂中的氯化二甲基丁酰基钾酰化式[V]的化合物以获得式[VI]的化合物，去保护式[VI]的化合物，然后水解以获得式[VII]的辛伐他汀铵盐，该铵盐内酯化以获得辛伐他汀。
• SCHUDA, ANN D.;VERHOEVEN, THOMAS R.;SHINKAI, ICHIRO
  作者：SCHUDA, ANN D.、VERHOEVEN, THOMAS R.、SHINKAI, ICHIRO

  DOI：——

  日期：——
• HOFFMAN, WILLIAM F.;LEE, TA J.;SMITH, ROBERT L;ROONEY, CLARENCE S.
  作者：HOFFMAN, WILLIAM F.、LEE, TA J.、SMITH, ROBERT L、ROONEY, CLARENCE S.

  DOI：——

  日期：——
• HYPOCHOLESTEROLEMIC, ANTI-INFLAMMATORY AND ANTIEPILEPTIC NEUROPROTECTIVE COMPOUND
  申请人：Burgos Muñoz Javier Santos

  公开号：US20130197073A1

  公开（公告）日：2013-08-01

  The present invention describes a compound of formula (I) its hydroxy acid form, the pharmaceutically acceptable salts of said hydroxy acid and pharmaceutically acceptable prodrugs and solvates of the compound and of its hydroxy acid form and, in particular, said compound, its hydroxy acid form, salts, etc. for use in the prevention of: neurodegenerative diseases, cognitive impairment, diseases associated with undesired oxidation, age-associated pathological processes and progeria, cardiovascular diseases such as atherosclerosis, atrial fibrillation, dyslipidemia, hypercholesterolemia, hyperlipidemia, and hypertriglyceridemia, inflammation or inflammatory processes, or epilepsy, epileptic seizures and convulsions.

  本发明描述了式(I)的化合物，其羟基酸形式，所述羟基酸的药学上可接受的盐，以及所述化合物及其羟基酸形式的药学上可接受的前药和溶剂化物，特别是所述化合物、其羟基酸形式、盐等用于预防：神经退行性疾病、认知障碍、与不良氧化相关的疾病、年龄相关的病理过程和早衰、心血管疾病，如动脉粥样硬化、心房颤动、血脂异常、高胆固醇血症、高脂血症和高甘油三酯血症、炎症或炎症过程，或癫痫、癫痫发作和惊厥。